TRUE BEARING DIAGNOSTICS, INC.

Executive Summary

April 2026

Company

True Bearing Diagnostics, Inc. (the "True Bearing") is developing *TruNAV*™, the world's first highly accurate, host driven, RNA derived, blood based diagnostic tool designed for infection detection. *TruNAV*™ will offer an agnostic approach diagnosing infection, selecting which basic type is involved (bacterial, viral, and/or biofilm), and measuring the infection's magnitude for ease of tracking therapies like antibiotics.

True Bearing was incorporated in 2017 to extend and commercialize certain research breakthroughs developed by the St. Laurent Institute and George Washington University's Center for Genomic Medicine. True Bearing´s mission is to introduce a collection of RNA-based blood tests that will drastically decrease the costs associated with the early-detection and treatment of multiple diseases and infections.

True Bearing started with a focus on coronary artery disease and, in 2020, with the arrival of COVID, pivoted to the diagnosis of infection. Overall, True Bearing is developing bio-marker panels that, it believes, will revolutionize the diagnosis across multiple diseases, *offering increased accuracy, delivered faster and cheaper.*

Highlights

- **Binary Decision and Magnitude of Infection**

Doctors lack a clear non-invasive tool to determine if infection is present or not. If present, what is its magnitude? Our greater than 90% accurate test allows for more effective, efficient results and diagnosis, enabling faster paths to addressing patient needs (including chronic abdominal pain, chronic sinus pain, hospital derived infection, orthopedic parts, appendicitis, urinary tract infections, biofilm, among others).

- **Solid Scientific Basis**

True Bearing has several publications with multiple research studies' confirmed data sets and patent coverage.

- **Over $100 billion potential savings** in the US alone[1].

- **Population Scale Triage Diagnostic**

Immediate diagnostic response offers identification and quarantine of sick people allowing for more efficient and effective treatment with minimal impact on economies.

- **Competitive Landscape**

Currently available tools include white blood cell count (+/- 60% accurate), CT scan (expensive), exploratory surgery (expensive and invasive). **We are offering a better test within an already existing market.**

Large Addressable Markets

The global infectious disease in-vitro diagnostics market size in 2023 was $77.9 billion[2] and is expected to grow by 4.5% (CAGR) annually through 2033. Growth is attributed to growing elderly population, technology advancements and increased funding for R&D in addition to increased public awareness and the push for Point of Care, (PoC) testing, lower cost solutions, AI inputs, and automation.

While the overall infectious disease market is very large, to facilitate the FDA Clearance process True Bearing's initial focus area is "assisting with diagnosis of abdominal infection" which is a $5.1 billion current addressable market.

Investment Opportunity

Building upon True Bearing's lead investor's initial contributions and with next round participation committed, the Company closed on initial tranche and seeks to complete raise ~$5 million in funding. With this infusion, True Bearing will be able to rapidly perform *TruNAV™'s* FDA clearance study, set up and/or align with a CLIA lab, develop payor relationships, and position itself for alignment with a strategic partner or sponsor.

Following FDA Clearance, next step Series-A equity financing and/or strategic partnership will enable an acceleration of expanded research, pipeline development, and scaled commercialization with a 5-year estimated trajectory as outlined below. We believe True Bearing estimates are conservative and include having analyzed real test sales ramp numbers from industry leaders including Veracyte - Afirma, Genomic Health - Oncotype DX, and Vermillion - Ova1.

	Post FDA Clearance				
($ in millions)	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	$9.7	$16.2	$51.7	$135.7	$193.9

Business Model

- Funding enables new lab setup, FDA clearance process, and payor relationship development.
- Leverage our partnerships with hospital groups and Key Opinion and industry Leaders participating in *TruNAV*™ FDA clearance validation study.
- FDA clearance and next larger round capital raise achieved – Launch early sales and marketing plan and commence post market studies. In addition, continue ongoing expanded research and pipeline development.
- Exit potential with licensing, strategic partner purchase, or IPO 1-2 years post FDA Clearance.

Company Contact: Tisha Jepson tjepson@truebearingdiagnostics.com

TRUE BEARING DIAGNOSTICS, INC.

Executive Summary

April 2026

Management Team

Tisha Jepson, CEO and Co-Founder. Executive Vice President at the St. Laurent Institute. Over 15 years developing tech start-ups, in the genetic sequencing space and with diagnostics research, development, and commercialization. Previously Director of Corporate Strategy at SeqLL, Inc.

Tim McCaffrey, Ph.D., CSO and Co-Founder. Professor of Genomic Medicine at GWU. Founded the Genomics Core Facility at Cornell. Board member at GW Heart & Vascular Institute and Cheney Cardiovascular Institute. NIH Merit Award recipient for the molecular genetics of vascular ageing.

Nora E. Baker, CFO. Over 25 years of finance and corporate development experience with leading global corporations. In 2023, founded strategic consulting firm offering financial, M&A advisory, and business educational services.

Solution:
We offer the gift of time – time to be living life through providing affordable, highly accurate, early diagnosis

Scientific Advisory Team

Chad Hoyt, M.D., F.A.C.C. - Advisor. Executive Director of Clinical Growth & Outreach, UVA Health System. Associate Professor of Medicine, Cardiovascular Division formerly, Cardiologist at Stroobants Cardiovascular Center and Executive Medical Director at Centra Heart & Vascular Center.

Lakhmir Chawla, M.D. - Advisor. Former Professor at GWU. Chief Medical Officer, Exthera Medical. Formerly at Silver Creek Pharmaceuticals and La Jolla Pharmaceutical. Prior Chief of Intensive Care Medicine, Veterans Affairs Medical Center.

Aamir Ali, M.D., PI – Advisor, Partner, Capital Digestive Care.

John Burczak, M.D. - Advisor. Formerly Global Head of R&D at GE Healthcare and Chief Scientist for Molecular Imaging and Diagnostics at GE Global Research.



Risks

- Risk - FDA clearance process may take longer than expected.

Mitigation – RUO - CLIA sales can be in place ahead of FDA clearance.

- Risk - CPT and insurance coverage may take longer than expected.

Mitigation - Generic CPT code can be utilized and Concierge medicine for cash business to ramp forward while achieving adoption through Insurance companies and CMS/ AMA.

Company Contact: Tisha Jepson tjepson@truebearingdiagnostics.com

TRUE BEARING DIAGNOSTICS, INC.

Executive Summary

April 2026

Publications and Patents

Publication. 2017/0356908 **Blood biomarkers for appendicitis and diagnostic methods using biomarkers**. December 14, 2017 (Chawla, McCaffrey, McPherson, & Kampf)

Publication. 2017/0369946. **Blood biomarkers for respiratory infections**. December 28, 2017 (Chawla & McCaffrey)

Publication. 2018/0135127. **Blood biomarkers for appendicitis and diagnostic methods using biomarkers**. May 17, 2018 (Chawla & McCaffrey)

US 10,851,418 B2. **Blood biomarkers for respiratory infections**. December 1, 2020 (McCaffrey & Chawla)

Publication 2018/006266. **Blood biomarkers for respiratory infections**. March 4, 2021 (Chawla & McCaffrey)

US 11,066,706. **Blood biomarkers for appendicitis and diagnostic methods using biomarkers**. July 20, 2021 (Chawla & McCaffrey)

Publication. Georges St. Laurent III, Ian Toma, Bernd Seilheimer, Konstantin Cesnulevicius, Myron Schultz, Michael Tackett, Jianhua Zhou, Maxim Ri, Dmitry Shtokalo, Denis Antonets, **Tisha Jepson,** and Timothy A. McCaffrey, **"RNAseq analysis of treatment-dependent signaling changes during inflammation in a mouse cutaneous wound healing model"**, BMC Genomics, (2021) 22:854 https://doi.org/10.1186/s12864-021-08083-2

Publication. Timothy A. McCaffrey, Ian Toma, Zhaoquing Yang, Richard Katz, Jonathan Reiner, Ramesh Mazhari, Palak Shah, Michael Tackett, Dan Jones, **Tisha Jepson**, Zachary Falk,Richard Wargodsky, Dmitry Shtakalo, Denis Antonets, Justin Ertle, Ju H. Kim, Yinglei Lai, Zeynep Arslan, Emily Aledort, Maha Alfaraidy and Georges St. Laurent III , **"RNA sequencing of blood in coronary artery disease: involvement of regulatory T cell imbalance"**, BMC Medical Genomics, McCaffrey *et al. BMC Med Genomics (2021) 14:216* https://doi.org/10.1186/s12920-021-01062-2

US 11,371,096 B2. Blood biomarkers for appendicitis and diagnostic methods using biomarkers. June 28, 2022 (Chawla & McCaffrey)

US 11,629,383 B2. Blood biomarkers for respiratory infections. April 18, 2023 (McCaffrey & Chawla)

Publication. Meltzer AC, Wargowsky RS, Moran S, Jordan T, Toma I, **Jepson T**, Shu S, Ma Y, McCaffrey TA. "**Diagnostic accuracy of novel mRNA blood biomarkers of infection to predict outcomes in emergency department patients with undifferentiated abdominal pain.**" *Scientific Reports*. 2023;13:2297. doi: 10.1038/s41598-023-29385

Publication. Dela Cruz P, Wargowsky R, Gonzalez A, Sifontes E, Shaykhinurov E, Jaatinen K, **Jepson T**, LaFleur J, Yamane D, Perkins J, et al. "**Blood RNA biomarkers identify bacterial and biofilm coinfections in COVID-19 intensive care patients"**. *Journal of Intensive Care Medicine*. May 2024. doi: 10.1177/08850666241251743

Publication. Jaatinen K, Shah P, Mazhari R, Hayden Z, Wargowsky R, **Jepson T**, Toma I, Perkins J, McCaffrey TA. **"RNAseq of INOCA patients identifies innate, invariant, and acquired immune changes: Potential autoimmune microvascular dysfunction."** *Frontiers in Cardiovascular Medicine* 2024

References

[1] The COVID-19 Pandemic and the $16 Trillion Virus

[2] In Vitro Diagnostics (IVD) Market Size Could Reach USD 120.49 Billion by 2033

Company Contact: Tisha Jepson tjepson@truebearingdiagnostics.com